MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ptr.70406

Медицинская библиотека · Phytotherapy research : PTR · 2026

Atractylenolide I Alleviates Lipotoxicity in Hepatocytes and Protects NAFLD in Mice Through SIRT1-Dependent IRE1α-XBP1 Pathway.

Zhuge Hui, Chang Kaixin, Sun Shuzhen, Ding Qinchao, Lai Shanglei, Dou Xiaobing, Song Qing, Li Songtao

СтатьяПеревод в очереди

Аннотация

Atractylenolide I (AO-I), a major pharmacological ingredient derived from Atractylodes macrocephala, has been reported to possess multiple bioactivities. This study aimed to investigate the potential protective effects of AO-I against lipotoxicity in both cultured hepatocytes and mice with non-alcoholic fatty liver disease (NAFLD). The NAFLD model was established by feeding C57BL/6 mice a high-fat diet (HFD) for 12 weeks. Oral administration of AO-I at doses of 20 or 50 mg/kg body weight per day was explored. Lipotoxicity in AML12 hepatocytes was induced by incubation with palmitate for in vitro investigations on the roles of AO-I. The results demonstrated that supplementation with AO-I improved alanine transaminase (ALT), aspartate transaminase (AST), and liver histology in NAFLD mice. Furthermore, AO-I directly alleviated palmitate-induced lipotoxicity by reducing hepatocyte death. Mechanistic studies revealed that AO-I significantly attenuated lipotoxicity through its potential resistance to endoplasmic reticulum (ER) stress and IRE1α-XBP1 splicing both in vivo and in vitro. We identified that AO-I substantially rescued HFD- and palmitate-induced SIRT1 decline in mouse livers and hepatocytes, respectively, thereby improving liver injury and hepatocyte cell death. Mechanistic studies demonstrated that the amelioration of ER stress and lipotoxicity by AO-I supplementation depended on SIRT1 activity. Moreover, AO-I also mitigated IRE1α activation-triggered JNK/p38 MAPK hyperphosphorylation. In conclusion, our findings suggest that AO-I exhibits significant therapeutic effects for improving lipotoxicity in the liver and may be considered as a candidate for NAFLD therapy.

Для цитирования: Zhuge Hui, Chang Kaixin, Sun Shuzhen, Ding Qinchao, Lai Shanglei, Dou Xiaobing, Song Qing, Li Songtao. Atractylenolide I Alleviates Lipotoxicity in Hepatocytes and Protects NAFLD in Mice Through SIRT1-Dependent IRE1α-XBP1 Pathway.. Phytotherapy research : PTR. 2026. DOI: 10.1002/ptr.70406.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.